Yagiz Matthew Akiska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yagiz Matthew Akiska has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Shawn G. Kwatra
Department of Dermatology, University of Maryland School of Medicine, Baltimore, USA
7 shared publications - Davies Gage
Department of Dermatology, University of Maryland School of Medicine , Baltimore, MD
3 shared publications - Deena Fayyad
Department of Dermatology University of Maryland School of Medicine Baltimore Maryland USA
3 shared publications - Emily Ma
Department of Dermatology, University of Maryland School of Medicine , Baltimore, MD
3 shared publications - Shahin Shahsavari
Department of Dermatology, University of Maryland School of Medicine , Baltimore, MD
3 shared publications Bharat Ranganath
From The George Washington University School of Medicine and Health Sciences, Washington, DC
2 shared publications
Latest Publications
- Open Access
- 6 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Ocular Events Temporally Associated With Minoxidil: A Structured Review
Minoxidil is widely used in topical form for androgenetic alopecia and is increasingly prescribed orally for hair disorders. Although cardiovascular and dermatologic adverse effects are well recognized, ocular complications associated with minoxidil exposure remain poorly characterized in the dermatologic literature. We conducted a structured review of published papers describing ocular adverse events temporally associated with oral or topical minoxidil (TM) use, following PRISMA guidelines. Twelve papers were identified, with a mean patient age of 33 years and predominance of male patients (83%). Exposure involved TM in 75% of cases, oral minoxidil in 8%, and combined use in 17%. Central serous chorioretinopathy was the most frequently reported event (58%), followed by retinal vascular occlusion (17%), nonarteritic anterior ischemic optic neuropathy (8%), ocular hypertension (8%), and transient optic nerve-associated visual disturbance (8%). Diagnostic confirmation was reported in all cases (100%). Discontinuation of minoxidil occurred in most cases (92%) and was frequently associated with clinical or anatomic improvement (83%); however, causality remained uncertain based on WHO-UMC and modified Naranjo assessments, with most cases categorized as possible adverse drug reactions. These findings highlight a rare but clinically relevant spectrum of ocular events temporally associated with minoxidil use. Clinicians should counsel patients to report new visual symptoms and consider ophthalmologic evaluation when indicated. Larger pharmacovigilance and observational studies are needed to better define incidence and underlying mechanisms.
- 6 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Open AccessOcular Events Temporally Associated With Minoxidil: A Structured Review
Minoxidil is widely used in topical form for androgenetic alopecia and is increasingly prescribed orally for hair disorders. Although cardiovascular and dermatologic adverse effects are well recognized, ocular complications associated with minoxidil exposure remain poorly characterized in the dermatologic literature. We conducted a structured review of published papers describing ocular adverse events temporally associated with oral or topical minoxidil (TM) use, following PRISMA guidelines. Twelve papers were identified, with a mean patient age of 33 years and predominance of male patients (83%). Exposure involved TM in 75% of cases, oral minoxidil in 8%, and combined use in 17%. Central serous chorioretinopathy was the most frequently reported event (58%), followed by retinal vascular occlusion (17%), nonarteritic anterior ischemic optic neuropathy (8%), ocular hypertension (8%), and transient optic nerve-associated visual disturbance (8%). Diagnostic confirmation was reported in all cases (100%). Discontinuation of minoxidil occurred in most cases (92%) and was frequently associated with clinical or anatomic improvement (83%); however, causality remained uncertain based on WHO-UMC and modified Naranjo assessments, with most cases categorized as possible adverse drug reactions. These findings highlight a rare but clinically relevant spectrum of ocular events temporally associated with minoxidil use. Clinicians should counsel patients to report new visual symptoms and consider ophthalmologic evaluation when indicated. Larger pharmacovigilance and observational studies are needed to better define incidence and underlying mechanisms.
- Open Access
- 23 June 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (6) , 1074-1076
Single-cell RNA sequencing reveals a distinct resident memory T-cell phenotype in prurigo nodularis
Prurigo nodularis (PN) is a chronic inflammatory skin disease with a poorly understood pathogenesis. We performed single-cell RNA sequencing on skin samples from patients with PN to characterize tissue-resident memory T-cell (TRM) subsets. Our findings reveal heterogeneous populations of PN CD4 TRMs in relation to the transcriptomes of atopic dermatitis and psoriasis, with immunological heterogeneity correlating with treatment response.
- 23 June 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (6) , 1074-1076
Open AccessSingle-cell RNA sequencing reveals a distinct resident memory T-cell phenotype in prurigo nodularis
Prurigo nodularis (PN) is a chronic inflammatory skin disease with a poorly understood pathogenesis. We performed single-cell RNA sequencing on skin samples from patients with PN to characterize tissue-resident memory T-cell (TRM) subsets. Our findings reveal heterogeneous populations of PN CD4 TRMs in relation to the transcriptomes of atopic dermatitis and psoriasis, with immunological heterogeneity correlating with treatment response.
- Open Access
- 13 January 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 706-723
Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review
Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment. This systematic review examines the diagnostic work‐up and therapeutic approaches for CPUO, evaluating the quality of treatment studies using the Strength of Recommendation Taxonomy (SORT) algorithm. Our paper also uniquely integrates a review of potential pathogenic mechanisms. A comprehensive literature search was conducted in PubMed, EMBASE, Ovid MEDLINE, and Cochrane databases through September 2025 using terms including “CPUO,” “chronic idiopathic pruritus,” and “pruritus of unknown origin.” Studies discussing pathogenesis, diagnostic strategies, or treatment were included. Treatment interventions were assessed based on the SORT algorithm. Of 228 identified records, 52 met inclusion criteria: 18 addressing pathogenesis, 5 discussing competing etiological hypotheses, 3 focusing on diagnostic work‐up, 23 on treatment, and 3 on non‐pharmacological therapies. CPUO pathogenesis appears multifactorial, involving Th2 dysregulation, neurogenic factors (JAK1, GRPR, TRPV4), metabolic alterations, and aging‐related immune changes. Current diagnostic approaches emphasize exclusion of systemic, dermatologic, and neurologic causes. Treatment options include topical agents (calcineurin inhibitors, capsaicin), systemic immunomodulators (JAK inhibitors, dupilumab, nemolizumab), neuromodulators (gabapentin, pregabalin), and phototherapy. However, available treatment studies are of low quality, with few randomized controlled trials (RCTs). CPUO remains a challenging condition with unclear pathophysiology and limited high‐quality therapeutic evidence. Further research, particularly RCTs, is needed to establish evidence‐based management strategies.
- 13 January 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 706-723
Open AccessPathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review
Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment. This systematic review examines the diagnostic work‐up and therapeutic approaches for CPUO, evaluating the quality of treatment studies using the Strength of Recommendation Taxonomy (SORT) algorithm. Our paper also uniquely integrates a review of potential pathogenic mechanisms. A comprehensive literature search was conducted in PubMed, EMBASE, Ovid MEDLINE, and Cochrane databases through September 2025 using terms including “CPUO,” “chronic idiopathic pruritus,” and “pruritus of unknown origin.” Studies discussing pathogenesis, diagnostic strategies, or treatment were included. Treatment interventions were assessed based on the SORT algorithm. Of 228 identified records, 52 met inclusion criteria: 18 addressing pathogenesis, 5 discussing competing etiological hypotheses, 3 focusing on diagnostic work‐up, 23 on treatment, and 3 on non‐pharmacological therapies. CPUO pathogenesis appears multifactorial, involving Th2 dysregulation, neurogenic factors (JAK1, GRPR, TRPV4), metabolic alterations, and aging‐related immune changes. Current diagnostic approaches emphasize exclusion of systemic, dermatologic, and neurologic causes. Treatment options include topical agents (calcineurin inhibitors, capsaicin), systemic immunomodulators (JAK inhibitors, dupilumab, nemolizumab), neuromodulators (gabapentin, pregabalin), and phototherapy. However, available treatment studies are of low quality, with few randomized controlled trials (RCTs). CPUO remains a challenging condition with unclear pathophysiology and limited high‐quality therapeutic evidence. Further research, particularly RCTs, is needed to establish evidence‐based management strategies.
- Open Access
- 18 October 2025
- Published by Elsevier in JID Innovations
- Vol. 6 (1) , 100422
Nanostring Transcriptomic Analysis Highlights IL-6 Family and TGF-β Pathways in the Pathogenesis of Prurigo Nodularis
- 18 October 2025
- Published by Elsevier in JID Innovations
- Vol. 6 (1) , 100422
Open AccessNanostring Transcriptomic Analysis Highlights IL-6 Family and TGF-β Pathways in the Pathogenesis of Prurigo Nodularis
- 14 October 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (1) , 128-142
Prevalence, incidence, and risk factors for dermatologic conditions in people with HIV in the modern antiretroviral era: A cohort study in Washington, DC
- 14 October 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (1) , 128-142
Prevalence, incidence, and risk factors for dermatologic conditions in people with HIV in the modern antiretroviral era: A cohort study in Washington, DC
- 6 August 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Epigenetic Profiling Reveals Neuroimmune and Fibrotic Pathway Dysregulation in Prurigo Nodularis
This study integrates genome-wide DNA methylation and transcriptomic profiling to reveal key dysregulated pathways in prurigo nodularis (PN). Lesional PN skin exhibits distinct epigenetic reprogramming that activates neuroimmune, fibrotic, and inflammatory gene networks, uncovering potential targets for precision therapies in chronic pruritic skin disease.
- 6 August 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Epigenetic Profiling Reveals Neuroimmune and Fibrotic Pathway Dysregulation in Prurigo Nodularis
This study integrates genome-wide DNA methylation and transcriptomic profiling to reveal key dysregulated pathways in prurigo nodularis (PN). Lesional PN skin exhibits distinct epigenetic reprogramming that activates neuroimmune, fibrotic, and inflammatory gene networks, uncovering potential targets for precision therapies in chronic pruritic skin disease.
- 17 June 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (1) , 62-66
A Scoping Review of Pruritic Papular Eruption in People Living With HIV
Pruritic papular eruption (PPE) is a chronic, intensely itchy skin condition commonly seen in people living with HIV (PLH). While PPE is well documented in regions with high HIV prevalence, its clinical presentation, risk factors, and treatment strategies in the United States remain poorly characterized. Thus, this study aims to fill critical gaps in understanding PPE among PLH in the United States by investigating its epidemiology, clinical features, and risk factors. A comprehensive literature search across PubMed, Google Scholar, and Cochrane identified 8 papers documenting 11 patients with PPE. Our results showed that the most commonly affected areas included the arms (82%), chest (45%), back (45%), face (36%), neck (36%), and anal cleft (18%). Seven patients (64%) had a concurrent bacterial or fungal infection with Candida albicans (42.9%) and Treponema pallidum (42.9%). Candida lesions were most commonly seen in the oral mucosa and inguinal or anal clefts. Overgrowth of commensal organisms such as Demodex folliculorum was also noted in or around the pilosebaceous units for 28.6% of patients. The most common treatment strategies include antiretroviral therapy and adjuvant corticosteroid or ultraviolet B phototherapy which helped relieve the pruritis associated with papulonodular lesions. These findings highlight how PPE may serve as a marker for severe immunosuppression among PLH. In HIV patients who present with a rapid onset of pruritic lesions, PPE should be a key consideration in the differential diagnosis. In these patients, thorough physical examination and further diagnostic evaluation for potentially associated infections is warranted.
- 17 June 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (1) , 62-66
A Scoping Review of Pruritic Papular Eruption in People Living With HIV
Pruritic papular eruption (PPE) is a chronic, intensely itchy skin condition commonly seen in people living with HIV (PLH). While PPE is well documented in regions with high HIV prevalence, its clinical presentation, risk factors, and treatment strategies in the United States remain poorly characterized. Thus, this study aims to fill critical gaps in understanding PPE among PLH in the United States by investigating its epidemiology, clinical features, and risk factors. A comprehensive literature search across PubMed, Google Scholar, and Cochrane identified 8 papers documenting 11 patients with PPE. Our results showed that the most commonly affected areas included the arms (82%), chest (45%), back (45%), face (36%), neck (36%), and anal cleft (18%). Seven patients (64%) had a concurrent bacterial or fungal infection with Candida albicans (42.9%) and Treponema pallidum (42.9%). Candida lesions were most commonly seen in the oral mucosa and inguinal or anal clefts. Overgrowth of commensal organisms such as Demodex folliculorum was also noted in or around the pilosebaceous units for 28.6% of patients. The most common treatment strategies include antiretroviral therapy and adjuvant corticosteroid or ultraviolet B phototherapy which helped relieve the pruritis associated with papulonodular lesions. These findings highlight how PPE may serve as a marker for severe immunosuppression among PLH. In HIV patients who present with a rapid onset of pruritic lesions, PPE should be a key consideration in the differential diagnosis. In these patients, thorough physical examination and further diagnostic evaluation for potentially associated infections is warranted.
- 27 February 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (7) , 1441-1443
Circulating IgE levels as a biomarker for treatment response to dupilumab among patients with prurigo nodularis
In this retrospective study, we investigated the role of baseline IgE levels in predicting the treatment response to dupilumab in patients with prurigo nodularis (PN). Our findings showed that patients with elevated IgE experienced significantly greater relief from pruritus following dupilumab treatment, suggesting that IgE could serve as a biomarker for identifying individuals who are more likely to benefit from treatments that target interleukin (IL)-4 and IL-13. These results support the development of personalized treatment strategies based on inflammatory profiles in patients with PN.
- 27 February 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (7) , 1441-1443
Circulating IgE levels as a biomarker for treatment response to dupilumab among patients with prurigo nodularis
In this retrospective study, we investigated the role of baseline IgE levels in predicting the treatment response to dupilumab in patients with prurigo nodularis (PN). Our findings showed that patients with elevated IgE experienced significantly greater relief from pruritus following dupilumab treatment, suggesting that IgE could serve as a biomarker for identifying individuals who are more likely to benefit from treatments that target interleukin (IL)-4 and IL-13. These results support the development of personalized treatment strategies based on inflammatory profiles in patients with PN.
- 4 December 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (4) , 755-757
Association of sleep disturbance and itch intensity with quality-of-life impairment and disease severity in prurigo nodularis
In this study, we explored the relationship between itch intensity, sleep disturbance and quality-of-life (QoL) impairment in patients with prurigo nodularis (PN). Using validated assessment tools, we found significant correlations between self-reported itch severity, objective disease measures, and their impact on sleep and QoL. These findings highlight the profound burden of PN on patients’ daily lives and the importance of addressing both itch and sleep disturbances in managing this condition.
- 4 December 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (4) , 755-757
Association of sleep disturbance and itch intensity with quality-of-life impairment and disease severity in prurigo nodularis
In this study, we explored the relationship between itch intensity, sleep disturbance and quality-of-life (QoL) impairment in patients with prurigo nodularis (PN). Using validated assessment tools, we found significant correlations between self-reported itch severity, objective disease measures, and their impact on sleep and QoL. These findings highlight the profound burden of PN on patients’ daily lives and the importance of addressing both itch and sleep disturbances in managing this condition.